Ania K. Knap, PhD – Entrepreneur-in-Residence, Advisor and Leadership Team, North Shore InnoVentures. Ania is also a co-founder and Partner in New England PharmAssociates, LLC, a life sciences executive and advisory services firm – and Sustaining Sponsor of NSIV. In 2004, she was a co-founder, President and Chief Scientific Officer of MaxThera, Inc, a pharmaceutical research company developing novel antibacterial agents to treat life-threatening infections caused by antibiotic resistant pathogens. MaxThera was formed through acquisition of the drug discovery portfolio Ania had developed as head of discovery research at Genome Therapeutics. The company was funded initially by the US BioShield Program and SBIR grants administered through the NIAID (NIH). MaxThera’s antibacterial assets were sold in 2010 to Biota Holdings Limited, a Melbourne Australia anti-infectives company. Prior to starting MaxThera, Ania was Sr. Director of Discovery Research at Genome Therapeutics, a role she took on following a her role as Head of Enzymology at Kinetix, In Cambridge, MA, where her expertise in kinase enzymology played a key role in preparing the company for its acquisition by Amgen. Prior to joining Kinetix she was Director of Biology at RiboGene, an anti-infectives company in Hayward, CA and a Project Team Leader in inflammation and cardiovascular therapeutics at Novartis (formerly Ciba-Geigy). Ania has a BS in Chemistry and Biology (minor in mathematics) from the University of Bridgeport, a PhD in biochemistry/enzymology from Wesleyan University and she was a post doctoral researcher in the lab of Nobel Laureate Sidney Altman at Yale University.